Bilobalide

Bilobalide: A Comprehensive Reference Article

1. Identity and Chemical Character

1.1 Names and Classification

Bilobalide is a biologically active terpenic trilactone present in Ginkgo biloba. It is classified as a sesquiterpenoid. As a sesquiterpenoid, it has a 15-carbon skeleton. From a structural point of view, the molecular skeleton of bilobalide consists of 15 carbon atoms arranged into four five-membered rings — one five-membered carbon ring and three five-membered lactone rings, which are mutually condensed, with a tertiary butyl group (rare in natural products) connected to these rings.

Ginkgolides and bilobalide are rare terpene trilactones isolated from Ginkgo biloba possessing interesting pharmacological properties. Bilobalide is structurally dense (1.63 mcbits/ų) and acts at GABA_A receptors as an antagonist. The high information density of bilobalide distinguishes it from other scaffolds and may characterize natural product space more generally.

1.2 Biosynthesis and Origin

Bilobalide is derived from geranylgeranyl pyrophosphate (GGPP), which is formed by addition of farnesyl pyrophosphate (FPP) to an isopentenyl pyrophosphate (IPP) unit to form a C15 sesquiterpene. Its exact synthesis pathway from farnesyl pyrophosphate is still unknown, though bilobalide and the ginkgolides share similar biosynthetic pathways, and bilobalide is thought to be formed by partial degradation of ginkgolide.

The ginkgo tree (Ginkgo biloba) is considered a living fossil due to its 200-million-year history under morphological stasis; its resilience is partly attributed to its unique set of specialized metabolites, in particular ginkgolides and bilobalide, which are chemically complex terpene trilactones. Researchers using a gene cluster-guided mining approach combined with co-expression analysis have revealed primary steps in ginkgolide biosynthesis, showing that five multifunctional cytochrome P450s with atypical catalytic activities generate the tert-butyl group and one of the lactone rings, characteristic of all G. biloba trilactone terpenoids.

1.3 Natural Source and Distribution in the Plant

Bilobalide is a main constituent of the terpenoids found in ginkgo leaves and also exists in minor amounts in the roots. Standardized ginkgo biloba extract (GBE) contains terpene trilactones — ginkgolides A, B, C, J and bilobalide — at a combined concentration of 5.4–6.6%, with ginkgolides A, B, and C together constituting 2.8–3.4% and bilobalide 2.6–3.2% of the extract, alongside a flavonoid fraction comprising 22–27% of the extract.

The host tree itself, Ginkgo biloba, is an ancient Chinese gymnosperm commonly known as "Bai Guo" and is the leading surviving member of the Ginkgoaceae family, which appeared approximately 250 million years ago, earning it the epithet "living fossil."

1.4 Common Dosage Forms and Preparations

Bilobalide is not typically isolated and sold as a standalone supplement for human use. Instead, it is consumed as part of standardized whole-leaf extracts of Ginkgo biloba. Various biological preparations made from Ginkgo biloba extract as raw materials are commonly used in medicines, dietary supplements, food additives, cosmetics, and functional beverages. The most extensively studied extract is EGb 761, a proprietary standardized preparation. The chemical constituents of EGb 761 are evaluated as follows: 22–27% of flavone glycosides, 2.8–3.4% of ginkgolide A, B, and C, 2.6–3.2% of bilobalide, and less than 5 ppm of ginkgolic acid.

Concentrated and partly purified products made from Ginkgo biloba constituents have been marketed widely under different trade names, for the treatment and management of cognitive deficiencies, other age-related impairments, and many other chronic and acute diseases such as cardiovascular and bronchial pathologies. These preparations come in the form of standardized tablets, tinctures, capsules, and intravenous formulations (the latter in regulated clinical settings outside the US). Preparations studied in human single-dose pharmacokinetic research have included formulations such as Geriaforce tincture, fresh plant extract tablets, and EGb 761, with various excipients.

Ginkgo leaves have long been used as bookmarks to protect against page-eating insects like silverfish and booklice, and the insecticidal activity of Ginkgo biloba leaves, roots, and stems may have provided an evolutionary advantage against predation to preserve the lineage of the early Paleocene species G. adiantoides.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

Ginkgo biloba was first recorded as a medicinal plant in the Chinese Materia Medica Shen Nong Ben Cao Jing approximately 2,000 years ago, and at that time only the seeds were reported to be used as medicine. Its seeds have been used as snacks and medical materials in Traditional Chinese Medicine (TCM), while over the last century its leaf extracts emerged as a source of rising pharmaceutical commerce related to brain health in Western medicine. Researchers have reviewed the 16th-century Chinese text, the Ben Cao Gang Mu by Li Shi-Zhen, to investigate ancient prescriptions of ginkgo seeds for skin infections.

Extracts from Ginkgo biloba have been used medicinally in TCM for thousands of years to treat circulatory problems, asthma, vertigo, fatigue, and tinnitus. The leaves, known as "Bai Guo Ye," were traditionally used to enhance blood circulation, support lung function, and improve cognitive clarity. Ancient Chinese medical texts including the Compendium of Materia Medica describe ginkgo leaves for resolving phlegm, supporting detoxification, and treating respiratory complaints. The leaves were often prepared as decoctions or combined with other herbs in formulas designed to "open the orifices" of the mind, a traditional description for enhancing mental clarity and memory.

It is important to note that bilobalide as an isolated compound was unknown to traditional practitioners — the entire tradition relates to preparations of Ginkgo biloba leaves and seeds containing bilobalide together with flavonoids, ginkgolides, and many other constituents. The identification of bilobalide as a discrete chemical entity and investigation of its individual properties are products of modern science.

2.2 Use in Japan and Korea

In Japan and Korea, ginkgo has also held a prominent place in traditional medicine for centuries; Japanese monks cultivated ginkgo trees in temple gardens, where they were revered for their beauty and perceived spiritual significance.

2.3 Transition to Western Phytomedicine

Ginkgo biloba L. is the only remaining species of the once large order Ginkgoales; its extraordinary botanical position and other peculiar properties have attracted the attention of scientists of different disciplines, including botanists, entomologists, natural products chemists, and pharmacologists. Clinical studies on the treatment of Alzheimer's disease with Ginkgo biloba L. leaf extract (EGb) have been reported since the 1980s, and many clinical studies have been carried out over the following 30 years.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Bilobalide in the Context of the Whole Extract

Bilobalide is one of several pharmacologically important constituents of standardized ginkgo extract. The extract also contains ginkgolides A, B, C, and J (diterpene trilactones) and a major flavonoid fraction. Standardized ginkgo biloba extract contains approximately 24% flavone glycosides (primarily quercetin, kaempferol, and isorhamnetin) and about 6% terpenoid lactones as its main active components. Research has increasingly focused on bilobalide as an individual bioactive agent with distinguishable effects.

3.2 GABA_A Receptor Antagonism

One of the most consistently characterized molecular mechanisms of bilobalide is its antagonism at ligand-gated ion channels, particularly GABA_A receptors. Studies have established equivalent effects of (−)-bilobalide and the nonconvulsive sesquiterpene (−)-jiadifenolide on action potential-independent inhibitory currents at GABAergic synapses, using (+)-bilobalide as a negative control. This GABA_A receptor antagonism has implications for both its neuroprotective properties and its risk profile (see Safety section). Bilobalide has been shown to significantly increase the amplitude of hippocampal population spikes in a muscimol-dependent manner and to decrease paired pulse inhibition, consistent with this pharmacological action. Both bilobalide and ginkgolide B have been demonstrated to shorten sleeping time during barbital-induced narcosis, and as constituents of Ginkgo biloba, they likewise activate the EEG, enhance the pro-convulsant effects of pentylenetetrazole (PTX), and trigger seizures in refractory epilepsy.

3.3 Mitochondrial Preservation and ATP Synthesis

In vitro and ex vivo studies indicate that bilobalide has multiple mechanisms of action that may be associated with neuroprotection, including its preservation of mitochondrial ATP synthesis, its inhibition of apoptotic damage induced by staurosporine or by serum-free medium, its suppression of hypoxia-induced membrane deterioration in the brain, and its actions of increasing the expression of the mitochondrial DNA-encoded COX III subunit of cytochrome c oxidase and the ND1 subunit of NADH dehydrogenase.

In ischemia models, treatment with bilobalide (10 mg/kg) before transient middle cerebral artery occlusion (tMCAO) improved respiratory capacity of mitochondrial complex I significantly when measured ex vivo. In addition, mitochondrial swelling induced ex vivo by calcium was used to estimate opening of the mitochondrial permeability transition pore; the changes induced by tMCAO were completely reversed when mice had received pretreatment with bilobalide.

3.4 Reduction of Excitotoxic Glutamate Release

As measured by microdialysis in the ischemic striatum, local perfusion with bilobalide (10 µM) reduced ischemia-induced glutamate release by 70% while glucose levels were not affected. Neuroprotection by bilobalide involves a mechanism in which the compound reverses ischemia-induced changes in mitochondria, leading to a reduction of glutamate release.

3.5 Antioxidant and Free Radical Scavenging

Both EGb 761 and bilobalide are protective against ischemia-induced neuronal death in vivo and glutamate-induced neuronal death in vitro by synergistic mechanisms involving anti-excitotoxicity, inhibition of free radical generation, scavenging of reactive oxygen species, and regulation of mitochondrial gene expression.

In astrocyte models, oxygen and glucose deprivation-reoxygenation downregulated manganese superoxide dismutase (MnSOD) and impaired mitochondrial function, which further enhanced ROS production in primary astrocytes — an effect that bilobalide was studied for its ability to mitigate via upregulation of MnSOD.

3.6 Anti-Inflammatory Signaling

Studies have demonstrated that bilobalide possesses an extensive range of pharmacological activities such as neuroprotective, antioxidative, anti-inflammatory, anti-ischemic, and cardiovascular protective activities. Several studies have reported that bilobalide can interfere with certain diseases by regulating autophagy; bilobalide inhibits LPS-induced neuroinflammation and promotes autophagy.

3.7 Pharmacokinetic Profile

Pharmacokinetic studies indicated that bilobalide may have the characteristics of rapid absorption, good bioavailability, wide distribution, and slow elimination. Bilobalide is a natural sesquiterpene trilactone from Ginkgo biloba leaves that has good water solubility and is widely used in food and pharmaceutical fields.

Human pharmacokinetic data show that bilobalide is approximately 70% bioavailable after oral intake of an 80–120 mg dose of ginkgo biloba leaf extract, with a half-life of approximately 3 hours. In this form, approximately 30–50% of bilobalide is excreted unchanged in the urine.

After oral administration of 30, 55, and 100 mg/kg ginkgo extract EGb 761 in animal studies, the pharmacokinetics of bilobalide and ginkgolides A and B were found to be dose-linear with half-lives of 2.2, 1.7, and 2.0 hours respectively, and clearance ranged from 24.2 to 37.6 mL/min/kg. In another pharmacokinetic study, the mean bioavailabilities of ginkgolide A, ginkgolide B, and bilobalide were found to be 80%, 88%, and 79%, respectively, with half-lives of 4.5, 10.6, and 3.2 hours, respectively.

Terpene lactones are orally bioavailable and predominantly eliminated via the renal pathway. The amounts of active compounds (terpene lactones) in administered products used in human single-dose pharmacokinetic studies were in the low-milligram range per dose.

4. Scientific Evidence by Area of Use

4.1 Neuroprotection and Cerebral Ischemia

Preclinical (animal and in vitro) evidence — extensive; clinical evidence — limited and indirect.

In vivo studies have indicated that systemically administered bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba leaf extracts, can reduce cerebral edema produced by triethyltin, decrease cortical infarct volume in certain stroke models, and reduce cerebral ischemia.

Neuroprotective properties of bilobalide were tested in a mouse model of stroke; after 24 hours of middle cerebral artery occlusion (MCAO), bilobalide reduced infarct areas in the core region (striatum) by 40–50% when given at 10 mg/kg one hour prior to MCAO. Sensorimotor function in mice was improved by bilobalide as shown by corner and chimney tests.

The researchers concluded that bilobalide is a strong neuroprotectant in vivo at doses that can be used therapeutically in humans, and that the mechanism of action evidently involves reduction of glutamate release, thereby reducing excitotoxicity.

In rat cerebellar neuronal cultures, addition of bilobalide protected in a dose-dependent manner against glutamate-induced excitotoxic neuronal death, with an effective concentration (EC₅₀) of 5 µg/mL (12 µM) for bilobalide and 100 µg/mL for EGb 761.

As multiple modes of action may apply to bilobalide, it could be useful in developing therapy for disorders involving cerebral ischemia and neurodegeneration. However, it must be emphasized that the neuroprotection data remain predominantly preclinical; direct human clinical trials isolating bilobalide's contribution are lacking, as human studies typically use the whole EGb extract.

4.2 Cognitive Function, Dementia, and Alzheimer's Disease

Clinical evidence — controversial and mixed; study quality variable.

Bilobalide is studied in the context of whole ginkgo extract (EGb 761) in human clinical trials for cognitive function. It cannot be separated from the extract's other components in these trials, limiting conclusions about bilobalide specifically.

As two important bioactive components of Ginkgo biloba extract (GbE), ginkgolides and bilobalide have been reported to show neuroprotective effects in Alzheimer's disease (AD) via multiple mechanisms such as anti-excitotoxicity, anti-inflammatory, and anti-oxidative activities.

Research into Ginkgo biloba has been ongoing for many years, while the benefit and adverse effects of Ginkgo biloba extract EGb 761 for cognitive impairment and dementia have been discussed controversially. A 2015 meta-analysis searched MEDLINE, EMBASE, Cochrane, and other databases for eligible randomized controlled trials; nine trials met the inclusion criteria, with trials of 22–26 weeks' duration including 2,561 patients in total. For the subgroup of patients with neuropsychiatric symptoms, 240 mg/day EGb 761 improved cognitive function, activities of daily living (ADLs), Clinical Global Impression of Change (CGIC), and neuropsychiatric symptoms with statistical superiority compared to other subgroups; for the Alzheimer's disease subgroup, the main outcomes were almost the same as the whole group of patients with no statistical superiority.

Clinical studies on the treatment of AD with Ginkgo biloba L. leaf extract have been reported since the 1980s, and many clinical studies have been carried out over the following 30 years; however, the benefits of EGb on the treatment of AD are still controversial. A 2019 review concluded that EGb may be able to improve cognitive function in patients who suffer from mild dementia during long-term administration (more than 24 weeks) and at an appropriate dosage (240 mg per day). Although a few available large-scale clinical trials suggest that EGb is relatively efficacious in delaying the progress of dementia, several other trials showed negative results.

The overall state of clinical evidence for cognitive outcomes is therefore mixed. Because bilobalide is always studied as a component of whole EGb 761 in human trials, attribution of specific effects to bilobalide alone is not possible from the available clinical data.

4.3 Anti-Inflammatory Effects

Preclinical evidence — moderate; human clinical evidence — absent for isolated bilobalide.

Bilobalide is a sesquiterpene compound extracted from Ginkgo biloba L. that has received widespread interest due to its anti-inflammatory, anti-oxidative, and neuroprotective properties; bilobalide exhibits vigorous anti-inflammatory activity, presenting it as an interesting potential therapeutic agent for osteoarthritis (OA).

In a 2022 study in a rat model of post-traumatic osteoarthritis, bilobalide was investigated for its effects on chondrocytes through the AMPK/SIRT1/mTOR signaling pathway. Several studies have reported that bilobalide can interfere with certain diseases by regulating autophagy. These findings are preclinical; controlled human trials examining bilobalide specifically for inflammatory conditions have not been conducted.

4.4 Oxidative Stress and Astrocyte Protection

Preclinical evidence only.

Bilobalide, a constituent of Ginkgo biloba extract, is a neuroprotective agent with multiple mechanisms of action; researchers have investigated its potential therapeutic effects in stroke, examining its effects on primary astrocytes using the oxygen and glucose deprivation-reoxygenation (OGD-R) model. Results show that OGD-R downregulated MnSOD and impaired mitochondrial function, which further enhanced ROS production in primary astrocytes — highlighting the cellular context in which bilobalide-mediated antioxidant activity is studied. No direct human clinical trial data exist for this specific mechanism.

4.5 Cardiovascular and Cardiac Ischemia

Preclinical evidence — limited; human clinical evidence — absent for isolated bilobalide.

Among the documented pharmacological activities of bilobalide is cardiovascular protective activity. Studies on neonatal rat cardiomyocytes have investigated anti-ischemic effects of bilobalide, including involvement of the platelet-activating factor receptor signaling pathway. These findings are preclinical only, and isolated bilobalide has not been tested in human cardiovascular clinical trials.

4.6 Alzheimer's Disease — Amyloid Pathology and Neuroinflammation

Preclinical evidence — emerging; human clinical evidence — indirect (through EGb 761 only).

Alzheimer's disease (AD) is an irreversible degenerative illness of the central nervous system with characteristic histological alterations known as amyloid plaques and neurofibrillary tangles; aggregation of plaques and tangles in the brain induces neurotoxicity and synaptic dysfunction, eventually contributing to neuronal cell death and neurodegeneration. A 2022 PubMed-indexed review proposed that ginkgolides and bilobalide have been reported to show neuroprotective effects in AD via multiple mechanisms such as anti-excitotoxicity, anti-inflammatory, and anti-oxidative activities.

A 2021 cell-biology study demonstrated that bilobalide inhibits inflammation and promotes the expression of amyloid-β (Aβ) degrading enzymes in astrocytes in AD cell models (PMC8528910). These are in vitro and animal data; no human trial has isolated bilobalide's role in amyloid clearance.

5. Body Systems and Health Areas Associated With Bilobalide

• Central Nervous System: Neuroprotection against ischemic and excitotoxic injury; modulation of GABA_A and glycine receptor activity; mitochondrial support in neurons and astrocytes; potential relevance to neurodegeneration (Alzheimer's disease, cerebrovascular disease).
• Cardiovascular System: Studies on the pharmacological activities of bilobalide have demonstrated anti-ischemic and cardiovascular protective activities.
• Musculoskeletal System: Anti-inflammatory effects in cartilage and chondrocyte models relevant to osteoarthritis; still preclinical.
• Immune and Inflammatory System: Inhibition of neuroinflammatory signaling (e.g., LPS-induced neuroinflammation); modulation of autophagy pathways.
• Antioxidant Defense: Scavenging of reactive oxygen species; upregulation of MnSOD; suppression of lipid peroxidation in neural tissues.

6. Dosage and Forms Reported in Studies

Bilobalide is not commercially available as a pure isolated supplement in standardized doses for the general public. It is typically consumed as a component of standardized ginkgo leaf extract. The following dosages are as reported in the cited scientific literature:

• Bilobalide is approximately 70% bioavailable after oral intake of an 80–120 mg dose of ginkgo biloba leaf extract.
• Clinical reviews suggest that EGb may be able to improve cognitive function in patients with mild dementia during long-term administration (more than 24 weeks) and at an appropriate dosage of 240 mg per day.
• In mouse stroke models, bilobalide reduced infarct areas by 40–50% when given at 10 mg/kg one hour prior to MCAO (preclinical dosage only).
• Local perfusion with bilobalide at 10 µM in microdialysis studies reduced ischemia-induced glutamate release by 70% (preclinical, in vivo dosage).
• In rat cerebellar neuronal cultures, the EC₅₀ for protection against glutamate-induced excitotoxic neuronal death was 5 µg/mL (12 µM) for bilobalide (in vitro dosage).
• The amounts of active terpene lactones (including bilobalide) in human pharmacokinetic study preparations were in the low-milligram range per dose.

A 2010 human pharmacokinetic study characterized the bioavailability and pharmacokinetics of bilobalide, ginkgolide A, and ginkgolide B after administration of three different Ginkgo biloba preparations (Geriaforce tincture, new Ginkgo fresh plant extract tablets, and EGb 761) in humans using LC-ESI-MS methodology. A sensitive LC-ESI-MS method with solid-phase extraction was established for the determination of bilobalide, ginkgolide A, and ginkgolide B in human plasma; bioavailability and pharmacokinetics of three different Ginkgo biloba L. preparations were investigated using single-dose pharmacokinetic study design.

7. Safety Considerations and Drug Interactions

7.1 Seizure Risk and GABA_A Antagonism

The most scientifically substantiated safety concern specific to bilobalide's mechanism is its interaction with inhibitory neurotransmitter systems. Both bilobalide and ginkgolide B have been demonstrated to shorten sleeping time during barbital-induced narcosis, and as constituents of Ginkgo biloba, they likewise activate the EEG, enhance the pro-convulsant effects of PTX, and trigger seizures in refractory epilepsy.

In epileptic patients or in patients who are prone to seizure, physicians should be cautious with the administration of ginkgo, as ginkgo toxin — mostly found in ginkgo seeds but still present in ginkgo leaves — could lower the seizure threshold. This toxin concern is distinct from bilobalide itself, but the GABA_A antagonism of bilobalide contributes independently to pro-convulsant risk in susceptible individuals.

7.2 Bleeding Risk and Antiplatelet/Anticoagulant Interactions

Out of 2,647 prescriptions analyzed in a retrospective observational study, 342 exhibited drug interactions with a prevalence rate of 12.94%; notably, Ginkgo biloba extract frequently interacts with antiplatelets, anticoagulants, and nonsteroidal anti-inflammatory drugs, with clopidogrel and aspirin exhibiting the highest prevalence rates of 2.61% each. Among the 747 patients analyzed for bleeding disorders, 31 (4.15%) exhibited bleeding symptoms.

7.3 CYP Enzyme Interactions

EGb doses higher than the recommended ones may lead to a weak induction of the CYP2C19-mediated omeprazole 5-hydroxylation and weak inhibition of the CYP3A4-mediated midazolam 1'-hydroxylation. Omeprazole was identified as a frequently interacting drug (2.34%) of mild severity in interaction analyses of ginkgo extract.

7.4 Regulatory Status

Dietary supplements such as Ginkgo biloba do not require extensive pre-marketing approval from the U.S. Food and Drug Administration; on multiple occasions, nutritional supplements may contain several ingredients, and a discrepancy between labeled and actual ingredients or their amounts may occur.

7.5 Toxicity Profile

Contact with or ingestion of ginkgo's seed can be poisonous; it can cause a serious allergic skin reaction such as acute generalized exanthematous pustulosis and also convulsions. These effects are primarily attributable to ginkgolic acids and 4-O-methylpyridoxine (ginkgotoxin) rather than to bilobalide directly. Benign effects of bilobalide in humans — in contrast to ginkgolides — commend it as a potentially safe molecule in some contexts (such as an insecticide).

A 2021 comprehensive review in Phytotherapy Research summarizes the advances in pharmacological, pharmacokinetics, toxicity, and safety studies of bilobalide in the last decade, with an emphasis on its neuroprotective and anti-inflammatory activities, noting limitations of relevant research and aspects that should be strengthened in future research.

7.6 Warfarin and Anticoagulant Interactions

Bleeding, seizure, and serotonin syndrome could be potential consequences of ginkgo toxicity. There is no antidote for ginkgo; treatment includes discontinuation of ginkgo and appropriate symptom control depending on the manifestation of each toxication case.

8. Evidence Strength Summary

• Neuroprotection (ischemia/excitotoxicity): Strong preclinical evidence across multiple animal and in vitro models; direct human clinical evidence for isolated bilobalide is absent. Human data relate only to whole EGb extracts, making attribution to bilobalide alone impossible.
• Cognitive function and dementia: Clinical evidence for EGb 761 is mixed and controversial. A 2015 meta-analysis of nine RCTs (n = 2,561) showed modest benefits in patients with neuropsychiatric symptoms at 240 mg/day over 22–26 weeks, but no statistical superiority for the Alzheimer's disease subgroup. Bilobalide's independent contribution is unknown.
• Anti-inflammatory effects: Moderate preclinical data in cell cultures and animal models; no human trials for isolated bilobalide.
• Cardiovascular protection: Preliminary preclinical findings; no human data for isolated bilobalide.
• Antioxidant activity: Well-characterized in vitro; limited in vivo corroboration in humans.
• GABA_A receptor antagonism: Mechanistically established in electrophysiology and pharmacology experiments; underlying pro-convulsant risk has documented clinical relevance for ginkgo extracts broadly.

References

• Bilobalide — Wikipedia
• Synthetic, Mechanistic and Biological Interrogation of Ginkgo biloba Chemical Space en route to (−)-Bilobalide — PMC / JACS
• A gene cluster in Ginkgo biloba encodes unique multifunctional cytochrome P450s that initiate ginkgolide biosynthesis — Nature Communications (2022)
• Bilobalide and Neuroprotection — PubMed / Pharmacology & Biochemistry of Behavior (2003)
• Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo — PubMed / Brain Research (2012)
• Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo — PMC
• Neuroprotection by bilobalide in ischemia: improvement of mitochondrial function — PubMed
• Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death — PubMed
• Bilobalide protects astrocytes from oxygen and glucose deprivation-induced oxidative injury by upregulating manganese superoxide dismutase — PubMed
• Ginkgolides and bilobalide for treatment of Alzheimer's disease and COVID-19: potential mechanisms of action — PubMed
• The neuroprotective mechanisms of ginkgolides and bilobalide in cerebral ischemic injury: a literature review — PubMed
• Bilobalide: A review of its pharmacology, pharmacokinetics, toxicity, and safety — PubMed / Phytotherapy Research (2021)
• Bilobalide: A review of its pharmacology, pharmacokinetics, toxicity, and safety — Phytotherapy Research (Wiley, 2021)
• Bilobalide — ScienceDirect Topics Overview
• Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans — PubMed
• An Updated Review of Randomized Clinical Trials Testing the Improvement of Cognitive Function of Ginkgo biloba Extract in Healthy People and Alzheimer's Patients — PMC / Frontiers in Pharmacology (2019)
• Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis — Journal of Alzheimer's Disease (2015)
• Bilobalide Exerts Anti-Inflammatory Effects on Chondrocytes Through the AMPK/SIRT1/mTOR Pathway — Frontiers in Pharmacology (2022)
• Bilobalide inhibits inflammation and promotes the expression of Aβ degrading enzymes in astrocytes to rescue neuronal deficiency in AD models — PMC / Translational Psychiatry (2021)
• Validation of a 16th Century Traditional Chinese Medicine Use of Ginkgo biloba as a Topical Antimicrobial — PMC / Frontiers in Microbiology (2019)
• Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's disease — PMC
• Ginkgo Biloba — StatPearls, NCBI Bookshelf
• Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis — PMC / PLOS ONE (2025)
• Ginkgo biloba: A Treasure of Functional Phytochemicals with Multimedicinal Applications — PMC
• Ginkgolides and bilobalide: Their physical, chromatographic and spectroscopic properties — ScienceDirect / Bioorganic & Medicinal Chemistry
• Ginkgo: Usefulness and Safety — NCCIH, National Institutes of Health